Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults.
A double-blind, randomized, controlled phase I study to assess the safety, immunogenicity, and antibody persistence of a new group A conjugate vaccine (PsA-TT) in volunteers aged 18 to 35 years was previously performed. Subjects received one dose of either the PsA-TT conjugate vaccine, meningococcal A/C polysaccharide vaccine (PsA/C), or tetanus toxoid vaccine. The conjugate vaccine was shown to be safe and immunogenic as demonstrated by a standardized group A-specific immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) and by a serum bactericidal antibody (SBA) assay using rabbit complement (rSBA). This report details further analysis of the sera using four additional immunologic assays to investigate the relationship between the different immunoassays. The immunoassays used were an SBA assay that used human complement (hSBA), a group A-specific IgG multiplexed bead assay, and two opsonophagocytic antibody (OPA) assays which used two different methodologies. For each vaccine group, geometric mean concentrations or geometric mean titers were determined for all assays before and 4, 24, and 48 weeks after vaccination. Pearson's correlation coefficients were used to assess the relationship between the six assays using data from all available visits. An excellent correlation was observed between the group A-specific IgG concentrations obtained by ELISA and those obtained by the multiplexed bead assay. hSBA and rSBA titers correlated moderately, although proportions of subjects with putatively protective titers and those demonstrating a > or = 4-fold rise were similar. The two OPA methods correlated weakly and achieved only a low correlation with the other immunoassays. The correlation between hSBA and group A-specific IgG was higher for the PsA-TT group than for the PsA/C group.
Findlow
H
H
Vaccine Evaluation Unit, Health Protection Agency North West, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, UK. Helen.findlow@hpa.org.uk
Plikaytis
B D
BD
Aase
A
A
Bash
M C
MC
Chadha
H
H
Elie
C
C
Laher
G
G
Martinez
J
J
Herstad
T
T
Newton
E
E
Viviani
S
S
Papaspyridis
C
C
Kulkarni
P
P
Wilding
M
M
Preziosi
M P
MP
Marchetti
E
E
Hassan-King
M
M
La Force
F M
FM
Carlone
G
G
Borrow
R
R
D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood*; D001770:Blood Bactericidal Activity / Q000276:immunology; D006801:Humans; D007118:Immunoassay / Q000379:methods; D007074:Immunoglobulin G / Q000097:blood; D008585:Meningitis, Meningococcal / Q000276:immunology*; D022401:Meningococcal Vaccines / Q000009:adverse effects / Q000276:immunology*; D038381:Neisseria meningitidis, Serogroup A / Q000276:immunology*; D009895:Opsonin Proteins / Q000097:blood; D010587:Phagocytosis / Q000276:immunology; D013223:Statistics as Topic; D017778:Vaccines, Combined / Q000276:immunology; D018074:Vaccines, Conjugate / Q000276:immunology; D055815:Young Adult
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022401:Meningococcal Vaccines; D009895:Opsonin Proteins; D017778:Vaccines, Combined; D018074:Vaccines, Conjugate